IRIDEX Business Summary

IRIDEX Corp (IRIX) is a global leader in the development and commercialization of laser-based medical systems and consumable instrumentation for the ophthalmology market, primarily focusing on the treatment of glaucoma and retinal diseases. The company generates revenue through a diversified mix of capital equipment sales (laser consoles), high-margin recurring sales of single-use delivery devices and procedure probes, and post-sale service and support contracts. Its proprietary MicroPulse technology, which delivers laser energy in short bursts to minimize tissue damage, serves as a core competitive differentiator across its flagship Cyclo G6 and Pascal product lines. As of early 2026, IRIDEX has successfully transitioned toward a more efficient operational model, achieving positive cash flow in late 2025 and projecting full-year revenue growth to approximately $52.7 million. Within the specialized ophthalmic laser landscape, IRIDEX competes directly with industry giants such as Alcon and Carl Zeiss Meditec, as well as focused players like Lumenis and Nova Eye Medical, maintaining a distinct niche as a pure-play innovator in non-invasive, tissue-sparing laser therapies. Founded in 1989 by Theodore A. Boutacoff and Dr. Robert E. Grove, the company is currently led by President and CEO Patrick Mercer, who assumed the role in October 2024 after serving as COO. Mercer, an electrical engineer with a background in the U.S. Navy’s Nuclear Power Program, is supported by CFO Romeo Dizon, a 35-year finance veteran who rejoined the firm in March 2025 to oversee its recapitalization. The leadership team is further bolstered by Executive Chairman Scott Shuda, a Managing Director at BlueLine Partners. A pivotal strategic shift occurred in March 2025 when Novel Inspiration International Co., Ltd. made a $10 million strategic investment in the company, leading to the appointment of former CEO William Moore and Clinico COO Nick Chen to the Board of Directors. This current leadership structure is focused on leveraging IRIDEX’s deep clinical pedigree to expand its footprint in the rapidly evolving glaucoma reimbursement landscape.